abstract of poster that was presented at the 30th CINP World Congress of Neuropsychopharmacology, 3-5 July, Seoul, Republic of Korea
Ellen E Ladenheim Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School...
Background: People with severe mental illness are two to three times more likely to be overweight or...
Liraglutide (LIR) is a novel long-lasting glucagon-like peptide-1 (GLP-1) analogue that facilitates ...
abstract of poster that was presented at the 30th CINP World Congress of Neuropsychopharmacology, 3-...
BACKGROUND: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cog...
© 2018 John Wiley & Sons Ltd Aims: To evaluate if glucagon-like peptide-1 receptor agonists (GLP-1RA...
Abstract Background Antipsychotic-induced weight gain constitutes a major unresolved clinical proble...
Mood disorder patients that are on long-term atypical antipsychotics treatment frequently experience...
Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major cl...
Patients with schizophrenia have higher cardio-metabolic risk, partially from antipsychotic-induced ...
Objectives: Cases of schizophrenia are commonly complicated with obesity and diabetes mellitus parti...
Background: Weight gain is a major side effect of antipsychotic treatment. Some atypical antipsychot...
Recent studies indicate a high comorbidity between type-2 diabetes mellitus (T2DM) and neurological ...
Ellen E Ladenheim Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School...
Background: People with severe mental illness are two to three times more likely to be overweight or...
Liraglutide (LIR) is a novel long-lasting glucagon-like peptide-1 (GLP-1) analogue that facilitates ...
abstract of poster that was presented at the 30th CINP World Congress of Neuropsychopharmacology, 3-...
BACKGROUND: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cog...
© 2018 John Wiley & Sons Ltd Aims: To evaluate if glucagon-like peptide-1 receptor agonists (GLP-1RA...
Abstract Background Antipsychotic-induced weight gain constitutes a major unresolved clinical proble...
Mood disorder patients that are on long-term atypical antipsychotics treatment frequently experience...
Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major cl...
Patients with schizophrenia have higher cardio-metabolic risk, partially from antipsychotic-induced ...
Objectives: Cases of schizophrenia are commonly complicated with obesity and diabetes mellitus parti...
Background: Weight gain is a major side effect of antipsychotic treatment. Some atypical antipsychot...
Recent studies indicate a high comorbidity between type-2 diabetes mellitus (T2DM) and neurological ...
Ellen E Ladenheim Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School...
Background: People with severe mental illness are two to three times more likely to be overweight or...
Liraglutide (LIR) is a novel long-lasting glucagon-like peptide-1 (GLP-1) analogue that facilitates ...
DOI
Add to ORKG